ES2902676T3 - Aminotriazolopiridinas como inhibidores de cinasa - Google Patents

Aminotriazolopiridinas como inhibidores de cinasa Download PDF

Info

Publication number
ES2902676T3
ES2902676T3 ES18707498T ES18707498T ES2902676T3 ES 2902676 T3 ES2902676 T3 ES 2902676T3 ES 18707498 T ES18707498 T ES 18707498T ES 18707498 T ES18707498 T ES 18707498T ES 2902676 T3 ES2902676 T3 ES 2902676T3
Authority
ES
Spain
Prior art keywords
pyridin
amino
triazolo
methyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18707498T
Other languages
English (en)
Spanish (es)
Inventor
Junqing Guo
Amy Hart
John Macor
Michael Mertzman
William Pitts
Steven Spergel
Scott Watterson
Murugaiah Subbaiah Murugaiah Andappan
Jie Chen
Carolyn Dzierba
Guanglin Luo
Jianliang Shi
Sing-Yuen Sit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2902676T3 publication Critical patent/ES2902676T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES18707498T 2017-02-13 2018-02-12 Aminotriazolopiridinas como inhibidores de cinasa Active ES2902676T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2902676T3 true ES2902676T3 (es) 2022-03-29

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18707498T Active ES2902676T3 (es) 2017-02-13 2018-02-12 Aminotriazolopiridinas como inhibidores de cinasa

Country Status (25)

Country Link
US (3) US10913738B2 (https=)
EP (1) EP3580220B1 (https=)
JP (1) JP7097373B2 (https=)
KR (1) KR102549952B1 (https=)
CN (1) CN110520423B (https=)
AU (1) AU2018217488B2 (https=)
BR (1) BR112019016635A2 (https=)
CA (1) CA3053484A1 (https=)
CY (1) CY1124978T1 (https=)
DK (1) DK3580220T3 (https=)
EA (1) EA039808B1 (https=)
ES (1) ES2902676T3 (https=)
HR (1) HRP20212000T1 (https=)
HU (1) HUE057801T2 (https=)
IL (1) IL268614B (https=)
LT (1) LT3580220T (https=)
MA (1) MA47460A (https=)
MX (1) MX378515B (https=)
PL (1) PL3580220T3 (https=)
PT (1) PT3580220T (https=)
RS (1) RS62801B1 (https=)
SG (1) SG11201907335UA (https=)
SI (1) SI3580220T1 (https=)
SM (1) SMT202200001T1 (https=)
WO (1) WO2018148626A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47460A (fr) * 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
HUE058292T2 (hu) * 2017-10-30 2022-07-28 Bristol Myers Squibb Co Aminoimidazopiridazinok mint kináz inhibitorok
CN112262139B (zh) 2018-01-26 2023-07-25 百时美施贵宝公司 作为激酶抑制剂的氨基吡咯并三嗪
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
AU2019302534B2 (en) * 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
AU2019339355A1 (en) * 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
TWI724753B (zh) * 2019-01-25 2021-04-11 大陸商北京賽特明強醫藥科技有限公司 醯胺基橋連雜環類化合物、及其組合物與應用
WO2020192562A1 (zh) * 2019-03-22 2020-10-01 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物,其制法与医药上的用途
ES2969756T3 (es) 2019-10-03 2024-05-22 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas
WO2021160109A1 (zh) * 2020-02-13 2021-08-19 劲方医药科技(上海)有限公司 二氢萘啶酮类化合物,其制法与医药上的用途
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
KR20240135076A (ko) 2021-08-10 2024-09-10 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
US20250197390A1 (en) 2022-03-16 2025-06-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused heterocyclic compound, and preparation method therefor and medical use thereof
CN116574053B (zh) * 2022-06-21 2026-04-14 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025072395A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570319A1 (en) 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
MX2010005700A (es) 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
JP5589003B2 (ja) 2009-02-04 2014-09-10 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 脂質障害のような代謝疾患の処置のために有用な[1,3]オキサジン−2−オンの誘導体
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
SG11201509351UA (en) 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3372604B1 (en) 2015-11-05 2021-12-01 Sumitomo Chemical Company, Limited Condensed heterocyclic compound
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
US11161843B2 (en) 2017-01-24 2021-11-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
MA47460A (fr) * 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
HUE058292T2 (hu) 2017-10-30 2022-07-28 Bristol Myers Squibb Co Aminoimidazopiridazinok mint kináz inhibitorok
CN112262139B (zh) 2018-01-26 2023-07-25 百时美施贵宝公司 作为激酶抑制剂的氨基吡咯并三嗪
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
RS62801B1 (sr) 2022-02-28
IL268614B (en) 2021-12-01
LT3580220T (lt) 2021-12-27
MX378515B (es) 2025-03-11
SG11201907335UA (en) 2019-09-27
SI3580220T1 (sl) 2022-01-31
AU2018217488A1 (en) 2019-10-03
CN110520423A (zh) 2019-11-29
EP3580220B1 (en) 2021-11-17
US20190389859A1 (en) 2019-12-26
EP3580220A1 (en) 2019-12-18
US10913738B2 (en) 2021-02-09
CN110520423B (zh) 2022-08-23
JP2020507582A (ja) 2020-03-12
PT3580220T (pt) 2022-01-03
BR112019016635A2 (pt) 2020-04-07
KR102549952B1 (ko) 2023-06-29
EA039808B1 (ru) 2022-03-16
MA47460A (fr) 2019-12-18
PL3580220T3 (pl) 2022-02-07
EA201991915A1 (ru) 2019-12-30
WO2018148626A1 (en) 2018-08-16
JP7097373B2 (ja) 2022-07-07
US12157733B2 (en) 2024-12-03
HRP20212000T1 (hr) 2022-04-01
AU2018217488B2 (en) 2021-09-23
SMT202200001T1 (it) 2022-03-21
DK3580220T3 (da) 2022-01-10
HUE057801T2 (hu) 2022-06-28
CY1124978T1 (el) 2023-01-05
MX2019009555A (es) 2019-10-02
CA3053484A1 (en) 2018-08-16
KR20190117006A (ko) 2019-10-15
US20220315580A1 (en) 2022-10-06
US20250074909A1 (en) 2025-03-06
IL268614A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
ES2902676T3 (es) Aminotriazolopiridinas como inhibidores de cinasa
AU2018361249B2 (en) Aminoimidazopyridazines as kinase inhibitors
US9695183B2 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
US11618753B2 (en) Aminopyrrolotriazines as kinase inhibitors
ES2936481T3 (es) 1H-Indazol-carboxamidas como inhibidores de la proteína cinasa 1 que interactúa con el receptor (RIPK1)
ES2997111T3 (en) Pyridazinyl amino derivatives as alk5 inhibitors
EA034931B1 (ru) Индолкарбоксамидные соединения
ES2945220T3 (es) Indazol carboxamidas como inhibidores de cinasas
RS59707B1 (sr) Derivati karbazola
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ
EA038420B1 (ru) Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m4